Natera, Inc. (NASDAQ:NTRA) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRAGet Rating) by 4.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,609 shares of the medical research company’s stock after selling 1,069 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Natera were worth $1,001,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. SG Americas Securities LLC grew its position in shares of Natera by 486.2% during the first quarter. SG Americas Securities LLC now owns 30,422 shares of the medical research company’s stock worth $1,238,000 after buying an additional 25,232 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new position in shares of Natera during the first quarter worth about $97,000. Kornitzer Capital Management Inc. KS grew its position in shares of Natera by 149.5% during the first quarter. Kornitzer Capital Management Inc. KS now owns 722,400 shares of the medical research company’s stock worth $29,387,000 after buying an additional 432,905 shares in the last quarter. EFG Asset Management North America Corp. grew its position in shares of Natera by 56.3% during the first quarter. EFG Asset Management North America Corp. now owns 79,264 shares of the medical research company’s stock worth $3,228,000 after buying an additional 28,544 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Natera by 4.6% during the first quarter. Exchange Traded Concepts LLC now owns 39,397 shares of the medical research company’s stock worth $1,603,000 after buying an additional 1,737 shares in the last quarter. 96.24% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 1,652 shares of the company’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total transaction of $59,075.52. Following the completion of the sale, the chief executive officer now owns 64,777 shares in the company, valued at $2,316,425.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Natera news, Chairman Matthew Rabinowitz acquired 219,820 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average price of $28.74 per share, with a total value of $6,317,626.80. Following the completion of the acquisition, the chairman now directly owns 420,000 shares of the company’s stock, valued at approximately $12,070,800. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 1,652 shares of the company’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $59,075.52. Following the transaction, the chief executive officer now directly owns 64,777 shares in the company, valued at approximately $2,316,425.52. The disclosure for this sale can be found here. Insiders sold 13,966 shares of company stock worth $550,755 over the last 90 days. 10.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

NTRA has been the subject of a number of analyst reports. Stephens initiated coverage on Natera in a research report on Monday, April 25th. They set an “overweight” rating and a $54.00 price objective for the company. The Goldman Sachs Group lowered their price target on Natera from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, April 19th. Cowen lowered their price target on Natera from $110.00 to $100.00 in a report on Friday, May 6th. Piper Sandler lowered their price target on Natera from $75.00 to $60.00 and set a “na” rating for the company in a report on Sunday, May 15th. Finally, Robert W. Baird lowered their price target on Natera from $100.00 to $71.00 in a report on Friday, May 6th. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.50.

Natera Price Performance

Shares of NASDAQ NTRA opened at $47.00 on Friday. The company has a current ratio of 4.24, a quick ratio of 4.13 and a debt-to-equity ratio of 0.52. Natera, Inc. has a twelve month low of $26.10 and a twelve month high of $129.09. The stock has a 50 day moving average of $39.15 and a two-hundred day moving average of $45.86. The stock has a market cap of $4.53 billion, a P/E ratio of -7.99 and a beta of 1.21.

Natera (NASDAQ:NTRAGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The medical research company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.05. Natera had a negative return on equity of 96.99% and a negative net margin of 81.90%. The company had revenue of $194.13 million during the quarter, compared to analysts’ expectations of $176.61 million. During the same quarter in the previous year, the business earned ($0.74) earnings per share. The firm’s revenue for the quarter was up 27.5% on a year-over-year basis. On average, research analysts forecast that Natera, Inc. will post -5.78 earnings per share for the current year.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAGet Rating).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.